Related Experiment Videos
Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in
Carla M Odio1, Tobias Ramirez, Gloria Arias
1Infectious Diseases, Hospital Nacional de Niños, San Jose, Costa Rica.
Insights
Dexamethasone significantly reduced long-term joint dysfunction and shortened symptom duration in children with septic arthritis. Early administration of this steroid benefits pediatric patients with bacterial joint infections.
Area of Science:
- Pediatric infectious diseases
- Rheumatology
- Pharmacology
Background:
- Septic arthritis affects 10–25% of children, often causing residual joint dysfunction.
- Cytokine levels in synovial fluid correlate with inflammation severity in bacterial arthritis.
- Dexamethasone has shown promise in reducing cartilage degradation in experimental arthritis models.
Purpose of the Study:
- To evaluate the efficacy of dexamethasone in reducing residual joint dysfunction.
- To assess the impact of dexamethasone on clinical recovery time in pediatric septic arthritis.
- To determine if early dexamethasone administration improves outcomes in children with hematogenous septic arthritis.
Main Methods:
- A double-blind, randomized study enrolled 123 children with suspected hematogenous bacterial arthritis.
- Participants received either a 4-day course of dexamethasone or a saline placebo.
- Antibiotic therapy was individualized based on patient age and identified pathogens.
Main Results:
- Dexamethasone significantly reduced residual joint dysfunction at the end of therapy, 6 months, and 12 months (P < 0.001).
- The duration of symptoms during the acute phase was also shortened with dexamethasone treatment (P = 0.001).
- The incidence of residual dysfunction in the dexamethasone group was significantly lower than in the placebo group.
Conclusions:
- A short course of dexamethasone effectively reduces residual joint dysfunction in children with hematogenous septic arthritis.
- Early administration of low-dose dexamethasone shortens symptom duration and improves outcomes.
- Dexamethasone is a beneficial adjunctive therapy for pediatric septic arthritis.
Background:
Septic arthritis is associated with residual dysfunction in 10 to 25% of affected children. Concentrations of cytokines detected in synovial fluid of children with bacterial arthritis correlate with the severity of inflammation. Treatment with dexamethasone decreased cartilage degradation in experimental Haemophilus influenzae b and Staphylococcus aureus arthritis.
Endpoints:
To decrease the number of patients with residual dysfunction of the affected joint at the end of therapy and at 6 and 12 months and to speed clinical recovery by the administration of dexamethasone.
Methods:
In a double blind manner we randomly selected 123 children with suspected hematogenous bacterial arthritis to receive dexamethasone or saline for 4 days. Antibiotic therapy was tailored according to age and the recovered pathogen.
Results:
Of the 123 children enrolled, 61 were assigned to the dexamethasone group and 62 to the placebo group. Only 50 and 50 patients in each group were evaluable. The 2 groups of patients were comparable with respect to age, sex, duration of symptoms, pathogen, affected joint and therapeutic and diagnostic procedures. Staphylococcus aureus accounted for 67% of the isolates, Haemophilus influenzae type b for 13% and Streptococcus pneumoniae for 9%. Dexamethasone therapy reduced residual dysfunction at the end of therapy, P = 0.000068; at 6 months, P = 0.00007; and at 12 months, P = 0.00053 of follow-up and shortened the duration of symptoms (P = 0.001) during the acute phase. The 26% incidence of residual dysfunction in the control patients was similar to the 25% found in other series.
Conclusions:
A short course of dexamethasone reduced residual joint dysfunction and shortened significantly the duration of symptoms in children with documented hematogenous septic arthritis. These results suggest that a 4-day course of low dose dexamethasone given early benefits children with hematogenous septic arthritis.